In the early 1900s, with the advent of new medical therapies and disease perspectives, novel strategies were employed to promote weight loss including thyroid hormone supplementation, and later, amphetamines [1]
It was developed in the 1990s by researchers at Monash University in Melbourne, Australia, with one goal: isolate the fat-burning portion of growth hormone and deliver those effects without the risks that come with full hGH administration
Starting Protocol Recommendations For individuals new to BPC-157 micro-dosing, a conservative starting approach allows assessment of individual response before optimization
Thus, it can create an internal environment more receptive to desire
Research with senescent rhesus monkeys (aged 20-27 years) showed that Epithalon administration decreased basal plasma levels of glucose and insulin while increasing basal nighttime melatonin levelsreversing age-associated endocrine dysfunction patterns